Hochgradig therapierelevante Studien, an denen das Studienzentrum der Neurologischen Praxis beteiligt ist

aktuelle Auswahl

Goadsby PJ1, Reuter U1, Hallström Y1, Broessner G1, Bonner JH1, Zhang F1, Sapra S1, Picard H1, Mikol DD1, Lenz RA1.
A Controlled Trial of Erenumab for Episodic Migraine.
N Engl J Med. 2017 Nov 30;377(22):2123-2132. doi: 10.1056/NEJMoa1705848.

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.
The Lancet Volume 391, No. 10127, p1263–1273, 31 March 2018

Stephen L Hauser , ASCLEPIOS I and ASCLEPIOS II Trial Groups
Ofatumumab versus Teriflunomide in Multiple Sclerosis
N Engl J Med 2020 Aug 6;383(6):546-557.